Passage Bio Inc (NAS:PASG)

$ 0.657 -0.0029 (-0.44%) Market Cap: 40.58 Mil Enterprise Value: -18.43 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 36/100

Passage Bio Inc to Review Interim FTD Data Transcript
Dec 20, 2023
Passage Bio Inc at Chardan Genetic Medicines Conference Transcript
Oct 02, 2023
Passage Bio Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Passage Bio Inc To Host Conference Call Transcript
Aug 07, 2023
Passage Bio Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Passage Bio Inc at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript
Apr 24, 2023
Passage Bio Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 03, 2023
Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion Transcript
Mar 07, 2023
Q4 2022 Passage Bio Inc Earnings Call Transcript
Mar 06, 2023

$1.23

Earnings
Passage Bio Inc PBGM01 Interim Clinical Data From Cohorts 1-3 of Imagine-1 Call Transcript
Dec 14, 2022
Q3 2022 Passage Bio Inc Earnings Call Transcript
Nov 10, 2022

$1.33 (+10.83%)

Earnings
Q2 2022 Passage Bio Inc Earnings Call Transcript
Aug 04, 2022

$2.13 (+0.95%)

Earnings
Passage Bio Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Q1 2022 Passage Bio Inc Earnings Call Transcript
May 16, 2022

$1.69 (-7.65%)

Earnings
Passage Bio Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Mar 31, 2022
Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) Transcript
Mar 08, 2022
Q4 2021 Passage Bio Inc Earnings Call Transcript
Mar 03, 2022

$3.05 (-11.59%)

Earnings
Passage Bio Inc at the 18th Annual WORLDSymposium Transcript
Feb 11, 2022
Passage Bio Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Passage Bio Inc Company Update Call Transcript
Dec 17, 2021
Q3 2021 Passage Bio Inc Earnings Call Transcript
Nov 04, 2021

$8.94 (+2.52%)

Earnings
Passage Bio Inc at Citi BioPharma Conference (Virtual) Transcript
Sep 08, 2021
Q2 2021 Passage Bio Inc Earnings Call Transcript
Aug 05, 2021

$12.64 (+5.77%)

Earnings
Passage Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Passage Bio Inc Virtual R&D Event Transcript
May 17, 2021
Q1 2021 Passage Bio Inc Earnings Call Transcript
May 05, 2021

$17.33 (-4.52%)

Earnings
Passage Bio Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 10, 2021
Q4 2020 Passage Bio Inc Earnings Call Transcript
Mar 03, 2021

$19.96 (+1.89%)

Earnings
Passage Bio, Inc. - Special Call Transcript
Jan 25, 2021
Passage Bio Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Q3 2020 Passage Bio Inc Earnings Call Transcript
Nov 10, 2020

$16.96 (+0.83%)

Earnings
Passage Bio Inc, Denali Therapeutics, and Prevail Therapeutics at Citi BioPharma Conference (Virtual) - Panel Transcript
Sep 10, 2020
Q2 2020 Passage Bio Inc Earnings Call Transcript
Aug 13, 2020

$15.37 (+4.06%)

Earnings
Passage Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Q1 2020 Passage Bio Inc Earnings Call Transcript
May 11, 2020

Earnings

Passage Bio Inc Virtual R&D Event Transcript

May 17, 2021 / 01:30PM GMT

Release Date Price: $14.82 (-4.39%)

Transcript

Eliseo Oreste Salinas

Passage Bio, Inc. - Chief Research & Development Officer and Interim Chief Medical Officer

Good morning. Welcome to the Passage Bio Research and Development Day. This is our second webinar series, focusing today in our program for frontotemporal dementia with progranulin deficiency. I am Eliseo Salinas, Chief R&D Officer at Passage Bio. But I am joined this morning by Bruce Goldsmith, CEO of Passage Bio; of the -- Jim Wilson, Head of the Genetic Therapy Program at the University of Pennsylvania; Christian Hinderer, Senior Director Research of Translational Medicine at GTP; and Gary Romano, Chief Medical Officer at Passage Bio. Next slide, please.

We will be making forward-looking statements in this presentation, so I encourage you to review our disclaimer if you haven't done so. Next slide, please.

So this is our program for this morning. I will make a brief introduction. Then we -- Christian Hinderer will be describing the preclinical findings at the origin of our program, PBFT02 and we'll have a break where we will be discussing the preclinical aspects

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.